论文部分内容阅读
This talk focuses on the implementation of participating MRCT in China.The key points of ICH E17 and China IMCT guideline will be reviewed; the sample size of Chinese patients in MRCT will be calculated based on normal distribution for two different requirements in both superiority and non-inferiority clinical trials.Potential solution of enrollment issues will be discussed.